Biological Containment of Genetically Modified<i> Bacillus subtilis</i> by Hosseini, Siamand et al.
Biological Containment of Genetically Modiﬁed Bacillus subtilis
Siamand Hosseini,a Alex Curilovs,b Simon M. Cuttinga,b
aSchool of Biological Sciences, Royal Holloway University of London, Egham, Surrey, United Kingdom
bSporeGen Ltd., Bourne Labs, Royal Holloway University of London, Egham, Surrey, United Kingdom
ABSTRACT Genetic manipulation of bacterial spores of the genus Bacillus has
shown potential for vaccination and for delivery of drugs or enzymes. Remarkably,
proteins displayed on the spore surface retain activity and generally are not de-
graded. The heat stability of spores, coupled with their desiccation resistance, makes
them suitable for delivery to humans or to animals by the oral route. Despite these
attributes, one regulatory obstacle has remained regarding the fate of recombinant
spores shed into the environment as viable spores. We have addressed the biologi-
cal containment of GMO spores by utilizing the concept of a thymineless death, a
phenomenon ﬁrst reported 6 decades ago. Using Bacillus subtilis, we have inserted
chimeric genes in the two thymidylate synthase genes, thyA and thyB, using a two-
step process. Insertion is made ﬁrst at thyA and then at thyB whereby resistance to
trimethoprim enables selection of recombinants. Importantly, this method requires
introduction of no new antibiotic resistance genes. Recombinant spores have a strict
dependence on thymine (or thymidine), and in its absence cells lyse and die. Inser-
tions are stable with no evidence for suppression or reversion. Using this system, we
have successfully created a number of spore vaccines as well as spores displaying
active enzymes.
IMPORTANCE Genetic manipulation of bacterial spores offers a number of exciting
possibilities for public and animal health, including their use as heat-stable vehicles
for delivering vaccines or enzymes. Despite this, one remaining problem is the fate
of recombinant spores released into the environment where they could survive in a
dormant form indeﬁnitely. We describe a solution whereby, following genetic ma-
nipulation, the bacterium is rendered dependent on thymine. As a consequence,
spores if released would produce bacteria unable to survive, and they would exhibit
a thymineless death due to rapid cessation of metabolism. The method we describe
has been validated using a number of exemplars and solves a critical problem for
containing spores of GMOs in the environment.
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Bacillus endospores, or spores, are dormant entities with well-known resistanceproperties, including heat stability and tolerance of exposure to noxious chemicals
and desiccation (1). As such, spores offer a number of applications. First and foremost
has been their use as mucosal vaccines wherein antigens can be displayed on the spore
surface by fusion to a coat protein anchor (2). Immunization of recombinant spores by
a mucosal route (oral, sublingual, or nasal) has shown promising results and in some
cases levels of protection that could be efﬁcacious in humans or animals (3–5). In the
case of the latter, the ability to incorporate a vaccine in feed is particularly attractive
and, for some animals, arguably the only way to vaccinate. For example, vaccinating
farmed shrimp against viral pathogens such as white spot syndrome virus (WSSV)
where recombinant spores expressing the WSSV VP26 and VP28 envelope proteins
have been shown to confer protection in shrimps (6–9). A number of Bacillus species are
considered food grade; that is, they are safe for human consumption, with a qualiﬁed
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presumption of safety (QPS) designation, as deﬁned by the European Food Safety
Authority (EFSA) (10). In the United States some Bacillus strains are considered “gen-
erally recognized as safe” (GRAS), as deﬁned by the Food and Drug Administration. QPS
and GRAS designations have supported the use of a number of Bacillus strains,
including those of Bacillus subtilis, as probiotics in both human and animal feeds (11).
The concept of recombinant probiotics (12), then, is a logical next step forward in
exploiting the beneﬁcial properties of Bacillus (13). In addition to use in vaccines, spores
have been shown to facilitate expression of enzymes on the spore surface, for example,
with the animal feed enzyme phytase (14). The ability to use probiotic bacteria that
deliver enzymes negates the need to purify enzymes and could offer signiﬁcant
advantages to industry. Finally, streptavidin (SA) has been expressed on B. subtilis
spores, enabling monoclonal antibodies to be conjugated to the spore surface and the
targeting of spores loaded with anticancer drugs to cancer cells (15).
Despite the potential utility of Bacillus spores for industrial applications, there
remain a number of obstacles regarding the deliberate release of genetically modiﬁed
Bacillus. First is the use of antibiotic resistance (AbR) genes used in the engineering of
stable recombinant strains. Regarding AbR, the majority of procedures requiring inser-
tion of heterologous DNA into B. subtilis require ectopic insertion using an AbR gene
for positive selection (16). Plasmid vectors carrying chloramphenicol or erythromycin
resistance genes are typically used for ectopic insertion at a genetic locus that is
redundant for cell growth, typically the alpha-amylase (amyE) or threonine C (thrC)
gene (17). The potential risk of AbR gene transfer following release is recognized, and
at least two systems in B. subtilis have now been described that enable insertion of
heterologous genes without introduction of an AbR gene (18, 19).
The second, and most challenging, hurdle is the ultimate fate of recombinant spores
once released since spores have been shown to be able to survive indeﬁnitely in the
environment (1). The soil is normally enriched with dormant spores (20), and their
intrinsic robustness makes it difﬁcult to argue that they would not persist after
deliberate release. One approach might be to construct germination-deﬁcient spores,
but, at best, the germination rate can be reduced to 0.0015% (21), which is unlikely to
satisfy regulatory authorities. One approach that could be considered is thymine
starvation resulting in a thymineless death, a concept that has been well documented
(22–24). Prokaryotes carrying a mutated thymidylate synthase gene are unable to
grow in low concentrations of thymidine or thymine, resulting in cell death. Thymine
starvation, then, is different from the biostatic effects commonly found with deprivation
of other nutrients. Thymineless death has been documented for B. subtilis (25), and the
bacterium carries two thymidylate synthase enzymes encoded by the thyA and thyB
genes (26).
We have adopted the principles of a thymineless death to exploit Bacillus for the
introduction of heterologous genes without the introduction of antibiotic resistance
genes. These recombinant spores, should they germinate, will fail to survive in the
environment and will die immediately. The approach we have developed is particularly
novel since it is a two-step gene integration process enabling positive selection on
successively higher levels of trimethoprim but without the introduction of any antibi-
otic resistance genes.
RESULTS AND DISCUSSION
Rationale. An absolute requirement for thymine in B. subtilis necessitates two
thymidylate synthases (TSase) encoded by the unlinked thyA (TSaseA) and thyB (TSaseB)
genes (26). These genes encode part of the folate biosynthetic pathway, which provides
pyrimidines for cell growth (see Fig. S2 in the supplemental material). TSaseB is
thermosensitive and retains only 5 to 8% activity at a restrictive temperature of 46°C.
Thus, inactivation of the thyA locus requires supplementation with thymine (or thymi-
dine) for growth at 46°C. TSaseA is not thermosensitive, and so inactivation of thyB
allows cells to grow at an elevated temperature. Inactivation of both thyA and thyB,
however, produces an absolute requirement of thymine for growth at both 37°C and
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46°C. As shown by Neuhard et al. (26), inactivation of the thy genes produces resistance
to the antifolate drug trimethoprim (or aminopterin) since the need for dihydrofolate
reductase (DHFR), the target for trimethoprim, is dispensed with. However, the levels of
resistance differ, with insertion at thyA producing a lower level of resistance than that
found in a thyA thyB mutant (26). This attribute of differential resistance to trim-
ethoprim enables a novel, two-step, ectopic cloning system to be designed (Fig. 1). In
the ﬁrst step, a gene is introduced at the thyA locus, and this is followed in the second
FIG 1 Strain constructions. To construct ectopic insertions at the thyA and thyB loci of B. subtilis, two
steps are required. In the ﬁrst step, a pThyA plasmid carrying a chimeric gene is linearized (ApaLI
digestion) and introduced into cells of a wild-type B. subtilis strain (in this case strain PY79) by
DNA-mediated transformation. Trimethoprim-resistant (Tmr) transformants are selected on SMM agar
containing trimethoprim (3 g/ml) and thymine (50 g/ml) and carry an insertion of homologous thyA
DNA together with the chimeric gene, by marker replacement, as shown. In the second step, linearized
plasmid DNA of a pThyB vector carrying the same or a different chimeric gene is introduced into cells
of the thyA insertion strain created in the ﬁrst step. Selection for Tmr is made on SMM-CAA agar
containing trimethoprim (6 g/ml) and thymine (50 g/ml).
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step by insertion at thyB using resistance to increasing concentrations of trimethoprim
for positive selection.
To demonstrate proof of concept for ectopic cloning at the thy loci, we chose a
number of heterologous genes whose products had previously been expressed on the
spore surface. In each case expression had been achieved by fusion to a B. subtilis gene
encoding a surface-expressed spore coat protein (either CotB or CotC). The proteins
chosen included the following: (i) VP26 and VP28, both envelope proteins of the shrimp
virus WSSV that when displayed on recombinant B. subtilis spores and incorporated in
feed have been shown to confer protection to shrimp challenged with WSSV (7–9); (ii)
a protein consisting of a C-terminal domain of Clostridium difﬁcile toxin A (TcdA26–39)
that, when expressed on the spore surface, has been shown to confer protection from
C. difﬁcile infection (CDI) in hamsters dosed orally with these recombinant spores (4, 27);
(iii) streptavidin (SA) that, when expressed on spores, can be conjugated to the
monoclonal antibody cetuximab, enabling targeting to colon cancer cells (15); (iv) two
enzymes, subtilisin E (AprE), an alkaline protease, and alpha-amylase (AmyE), which
are both enzymes of industrial importance and commonly incorporated in animal
feed (28, 29).
A two-step method for ectopic gene insertion. Two plasmids, pThyA and pThyB,
were synthesized that carry the complete thyA or thyB gene interrupted at midpoint
with a multiple cloning site (MCS) for insertion of heterologous DNA (Fig. 1 and Table
S1). To ensure sufﬁcient DNA homology to enable a double-crossover recombination
event, the left and right arms carried the relevant thy segments as well as ﬂanking
upstream or downstream DNA (900 bp at the proximal and distal ends). In-frame
fusions of the cotB and cotC genes (encoding the spore coat anchors required for
display of heterologous proteins) to the open reading frame (ORF) of vp26, vp28,
tcdA26–39, the SA gene, aprE, or amyE (Fig. S1A to E) were then cloned into the
appropriate pThyA or pThyB vector. The pThyA plasmids were next linearized and used
to transform competent cells of the wild-type strain PY79 with selection for trim-
ethoprim resistance on plates supplemented with trimethoprim (3 g/ml) and thymine
at 37°C. Transformants carrying thyA insertions could be recognized by their failure to
grow at 46°C without thymine. In the second step, for introduction of insertions at the
thyB locus, classical DNA-mediated transformation of competent cells with the pThyB
plasmid proved inefﬁcient, with low integration frequencies. Instead, we developed an
electroporation method that reliably and reproducibly enabled introduction of pThyB
plasmids at the thyB locus in strains lacking thyA (see Materials and Methods) using
selection with a higher concentration of trimethoprim (6 g/ml). Strains carrying
insertions at thyA and thyB were veriﬁed by their failure to grow at both 37°C and 46°C
in the absence of thymine. Using this two-step process, we successfully constructed a
number of strains carrying insertions (vp26, vp28, tcdA26–39, and the SA gene) at the
thyA and thyB loci (Table 1). In addition, we also made strains carrying single insertions
of the aprE and amyE genes at the thyA locus. To create an absolute thymine depen-
dence, we simply linearized an empty pThyB plasmid and introduced this DNA into the
thyA mutant selecting for trimethoprim at 6 g/ml. Strains we successfully constructed
included monovalent (VP28, TcdA26–39, streptavidin, subtilisin E, and amylase) as well
as divalent (expression of VP26 and VP28 on one spore) expression by fusion to one or
two different spore coat anchors (CotB and CotC). For each strain constructed and listed
in Table 1, we conﬁrmed by nucleotide sequence analysis the integrity of the thyA or
thyB insertion.
We examined growth of the insertions in Spizizen’s minimal medium (SMM) at 37°C;
Fig. 2 shows examples of a strain (SH14) carrying cotB-tcdA26–39 and cotC-tcdA26–39
insertions at the thyA and thyB loci. As expected, the strain with the thyA insertion grew
normally with or without thymine (Fig. 2B) and was indistinguishable from wild-type
PY79 (Fig. 2A). In contrast, the thyA thyB insertion strain was thymine dependent but in
the presence of thymine had reduced ﬁtness, as shown from the lower maximal optical
density (OD) (Fig. 2C).
Hosseini et al. Applied and Environmental Microbiology
February 2018 Volume 84 Issue 3 e02334-17 aem.asm.org 4
 o
n
 M
arch 8, 2019 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
In addition, using whole-genome sequencing, we conﬁrmed that strain SH12 (thyA::
cotC-vp26 thyB::cotB-vp28) and SH14 (thyA::cotB-tcdA26–39 thyA::cotC-tcdA26–39) carried
the speciﬁc insertions at the thy loci without any chromosomal aberrations (data not
shown). Expression of chimeric proteins was conﬁrmed by Western blotting of proteins
extracted from puriﬁed spores. Figure 3 shows blots for detection of the VP26, VP28,
TcdA26–39, and SA chimeras in SH12, SH14, and SH16, which demonstrated bands of the
expected molecular masses. A second method was detection of whole spores by
enzyme-linked immunosorbent assay (ELISA) using polyclonal antibodies to the corre-
sponding heterologous antigen. Figure 4 shows surface detection of the TcdA26–39 (Fig.
4A) and VP28 (Fig. 4B) antigens by whole-spore ELISA. As expected, levels of the
TcdA26–39 protein carried at both the thyA and thyB loci (Fig. 4A, SH14) were greater
than the expression level at one locus (i.e., thyA, SH13). In parallel, we also measured the
abundance of TcdA26–39 in spores of PP108 that carried the same antigen fused to CotB
and CotC but inserted at the thrC and amyE loci, respectively (4). Expression levels were
somewhat lower, but it should be noted that when an anti-spore polyclonal antibody
(PAb) was used to measure levels of spore coat proteins, expression levels were
correspondingly reduced.
Both thymine and thymidine could be used for growth of strains carrying insertions
in the thyA and thyB loci. Using SH14, we showed that, for optimal growth, 15 g/ml
TABLE 1 Phenotypes of B. subtilis recombinant strains
Strain Genotype
Growth at
37°Ca
Growth at
46°Ca
Trimethoprim MIC
(mg/ml)b
Sporulation (CFU/ml [% of total])c
 Thy  Thy  Thy  Thy
Total no. of
spores
No. of heat-resistant
spores
PY79 thyA thyB     0.25 2.8  108 2.4  108 (85.7)
SH11 thyA::cotC-vp26     16 1.9  108 1.6  108 (82)
SH12 thyA::cotC-vp26 thyB::cotB-vp28     64 2  108 1.5  108 (75)
AC01 thyA::cotB-vp28     16 2.6  108 2.2  108 (85)
AC02 thyA::cotB-vp28 thyB::cotB-vp28     64 1.9  108 1.5  108 (78.6)
SH13 thyA::cotB-tcdA26–39     16 2.2  108 1.8  108 (85)
SH14 thyA::cotB-tcdA26–39 thyB::cotC-tcdA26–39     64 2.5  108 1.9  108 (77.2)
SH15 thyA::cotB-SA gene     16 2.8  108 2.3  108 (82)
SH16 thyA::cotB-SA gene thyB::cotB-SA gene     64 3.1  108 2.4  108 (77.4)
SH17 thyA::cotB-amyE     16 7.4  108 6.1  108 (82.5)
SH18 thyA::cotB-amyE thyB::MCS     64 1.28  108 9.8  107 (76.5)
SH19 thyA::cotB-aprE     16 4.1  108 3.7  108 (90)
SH20 thyA::cotB-aprE thyB::MCS     64 8.1  107 6.8  107 (83.9)
aGrowth () or no growth () on SMM agar with or without thymine (50 g/ml).
bThe MIC was determined using a microdilution method (51).
cSpores were from cultures grown overnight in DSM (with thymine) at 37°C.
FIG 2 Growth of strains in minimal medium. Wild-type PY79 (A), SH13 thyA::cotB-tcdA26–39 (B), and SH14 thyA::cotB-tcdA26–39
thyB::cotC-tcdA26–39 (C) were grown in SMM at 37°C with (ﬁlled symbols) or without (open symbols) thymine supplementation (50
g/ml).
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of thymine or 20 g/ml of thymidine was sufﬁcient (Fig. S3). This was signiﬁcantly less
than the 50 g/ml reported before (26) and most probably reﬂects differences in the
backgrounds of the strains used. Cells carrying insertions at the thyA and thyB loci,
although able to grow in medium supplemented with thymine, underwent a massive
loss in cell viability (5 logs in 5 h) when thymine was removed, a hallmark of a
thymineless death (Fig. S4).
Finally, using this cloning system, we were able to introduce insertions that were of
the same or opposite transcriptional polarity to the respective thy gene (Fig. S1A to E),
indicating no evidence of readthrough from the proximal thy coding sequences.
Experimental considerations for use of ectopic insertion at the thy loci. (i)
Growth in rich medium. In rich medium such as LB medium and Difco sporulation
medium (DSM), the single thyA insertion strain was able to grow at 37°C without
thymine supplementation while the thyA thyB strain with the double insertion showed
no growth (Fig. 5B and D). Intriguingly, supplementing LB medium or DSM with
FIG 3 Spore coat expression. B. subtilis strains carrying insertions at the thyA and thyB loci were examined by Western blotting of spore
coat proteins extracted from preparations of pure spores. Panels show bands obtained in extracts of wild-type spores (PY), spores
carrying thyA and thyB insertions (AB), or spores carrying only a thyA insertion (A). Panels A and B show analysis of SH12 thyA::cotB-vp28
thyB::cotC-vp26 with anti-VP28 and anti-VP26 antibodies. Panel C shows analysis of SH14 thyA::cotB-tcdA26–39 thyB::cotC-tcdA26–39 with
TcdA26–39-speciﬁc antibodies. Panel D shows analysis of SH16 thyA::cotB-SA gene thyB::cotB-SA gene with SA-speciﬁc antibodies. Bands
corresponding to the chimeric proteins are indicated (*) with the relevant coat protein anchor (CotB or CotC). The protein loaded per
well corresponded to an extraction from 2  108 spores (see Materials and Methods).
FIG 4 Surface expression determined by whole-spore ELISA. (A) Microtiter plates were coated with spores (2  108
spores/well) of PY79 (spo), PP108 (amyE::cotC-tcdA26–39 thrC::cotB-tcdA26–39), SH13 (thyA::cotB-tcdA26–39), and SH14
(thyA::cotB-tcdA26–39 thyB::cotC-tcdA26–39) and then probed with either anti-spore (1:1,000) or anti-TcdA26–39 (1:500)
rabbit PAb. Secondary PAbs were diluted 1:5,000, and naive serum was used for comparison, with basal levels
subtracted. (B) The experiment as described for panel A but using spores of PY79, AC01 (thyA::cotB-vp28) and AC02
(thyA::cotB-vp28 thyB::cotB-vp28) probed with either anti-spore (1:1,000) or anti-VP28 (1:300) rabbit PAb.
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thymine did not restore normal levels of growth. In LB medium the double-insertion
strain failed to grow (Fig. 5A), while in DSM plus thymine, limited growth was observed
(Fig. 5C). However, after 24 h of growth in DSM, sporulation was shown to have
occurred, and the numbers of heat-resistant spores were essentially equivalent to those
of PY79 (Table 1).
Since the thyA thyB insertion strain could grow, albeit with reduced ﬁtness, in
minimal medium supplemented with thymine (Fig. 2C), we reasoned that one or more
components of the rich medium might inhibit growth potentially by interfering with
the folate pathway. A prime candidate was yeast extract (YE) that is present in LB
medium and DSM at 5 mg/ml and 2 mg/ml, respectively, and absent in SMM. YE has
been shown to inhibit thymine mutants of Escherichia coli strains, and the active
bactericidal ingredient has been identiﬁed as adenosine (30). A second possibility,
though, was p-aminobenzoic acid (31), a component of YE and directly involved in the
folate pathway (Fig. S1) but also found to be bactericidal to E. coli (32).
We grew strains (thy and thyA thyB) in LB medium with thymine with various levels
of YE and found that YE concentrations of 2 mg/ml inhibited growth of strains
carrying two thy (thyA and thyB) insertions (Fig. S5). The inhibitory activity of YE could
therefore explain why in LB medium the thyA thyB double-insertion strain failed to grow
in the presence of thymine (Fig. 5A). Similarly, in DSM, where YE is present at a lower
concentration, reduced growth was observed (Fig. 5C). Finally, the inhibitory action of
YE necessitated the need for a modiﬁed growth medium (SOC2) lacking YE for
preparation of cells for the electroporation step used in the strain constructions (see
Materials and Methods). Although YE clearly inhibits growth, we have been unable to
attribute this deﬁnitively to either adenosine or p-aminobenzoic acid (data not shown).
FIG 5 Growth of strains in rich medium. Growth at 37°C under the indicated conditions is shown for PY79
(), SH13 (), and SH14 (Œ). Thymine was used at 50 g/ml.
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(ii) Gene transfer. As mentioned earlier, DNA-mediated transformation of compe-
tent cells could be used to introduce plasmid DNA into B. subtilis cells. However, for
introducing DNA into thyA cells in the second step, electroporation using a modiﬁed
medium lacking YE yielded higher frequencies of integration.
We found that following the ﬁrst genetic cross, two colony types, in equal propor-
tions, were apparent on SMM agar supplemented with thymine and trimethoprim
(3 g/ml) (Fig. S6). Type 1 colonies were large and opaque (2 to 3 mm), and type 2
colonies were translucent, smaller (1 mm), and grew slowly. All colonies could grow at
46°C in the presence of thymine, indicating prima facie a thyA insertion. However, only
about one-third of type 1 colonies were found, using PCR, to carry stable thyA insertions
while no type 2 colonies carried insertions. We assume that these colonies able to grow
on trimethoprim plates must carry some form of compensatory, yet unstable, muta-
tion(s) allowing growth in the presence of the antibiotic.
A second important ﬁnding was that for the second genetic transfer, recombinants
could be selected only on SMM supplemented with thymine, trimethoprim (6 g/ml),
and Casamino Acids (CAA). If plated directly onto agar lacking CAA, small (1 mm),
slow-growing colonies would result, but after reculturing these were found to have lost
the thyB insertion, as determined by colony PCR. Even in the presence of CAA, all
colonies were small, and only about 20% of those growing on trimethoprim (6 g/ml)
carried a stable thyB insertion. Work in E. coli as well as in B. subtilis has shown that
disruption of the folate pathway can lead to depletion of key amino acids as well as of
purines and pyrimidines (33, 34). Trimethoprim-mediated inactivation of dihydrofolic
acid reductase (DHFR) would deplete intracellular levels of tetrahydrofolic acid (THF),
methylenetetrahydrofolic acid (MTHF), and dihydrofolate (DHF). In turn, this would
affect the reversible interconversion of serine and glycine with THF, a vital reaction in
the synthesis of purines and catalyzed by a serine hydroxymethyltransferase ([SHMT] or
GlyA) (35, 36). MTHF is also utilized in the ﬁnal step of the biosynthetic pathways of
cysteine and methionine (37), and disruption of the pathway by the thyA thyB alleles
could introduce a requirement for methionine.
We measured the growth of the thyA thyB insertion strain SH14 in SMM supple-
mented with CAA, adenine, and thymine (Fig. S7). In the presence of trimethoprim
(6 g/ml) growth was optimal, reaching a maximal OD at 600 nm (OD600) of 2 only
in SMM containing CAA, while in medium containing no CAA or carrying only adenine
and/or thymine, growth was markedly reduced. In the absence of trimethoprim, growth
of SH14 remained weak compared to that of the wild-type strain PY79. Growth,
however, was superior to that in the presence of the antibiotic and was restored to
normal ﬁtness only in the presence of CAA. Trimethoprim therefore disrupts the folate
pathway, signiﬁcantly reducing strain ﬁtness, and this could not be restored by sup-
plementation with purines or pyrimidines but only with CAA.
Therefore, for the second genetic transfer step (i.e., for construction of the double,
thyA thyB, insertion), selective medium must provide all amino acids. However, once the
strain is constructed, the use of trimethoprim is no longer required, and strains can be
cultivated on any medium so long as three criteria are met: ﬁrst, that the medium
contains thymine or thymidine; second, that YE is either absent or at a concentration
less than 2 mg/ml; and third, that amino acids are provided in the growth medium.
(iii) Choice of one coat protein anchor. For expression of heterologous proteins on
the spore surface, the coat proteins CotB and CotC can be used for both mono- and
divalent expression. As expected, when two different spore coat anchors were used,
protein expression was higher than when only one anchor was used. So, as shown in
Fig. 4A, TcdA26–39 levels were higher in SH14 spores carrying thyA::cotB-tcdA26–39 and
thyB::cotC-tcdA26–39 insertions than in SH13 spores carrying only a thyA::cotB-tcdA26–39
insertion. Interestingly, using fusion of VP28 to CotB and insertion of this chimera at the
thyA locus alone (strain AC01) or at both the thyA and thyB loci (strain AC02) led to
higher levels of expression in the latter. This ﬁnding requires some consideration since
it might be assumed that each spore would carry a deﬁned number of CotB monomers
Hosseini et al. Applied and Environmental Microbiology
February 2018 Volume 84 Issue 3 e02334-17 aem.asm.org 8
 o
n
 M
arch 8, 2019 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
that could assemble onto the spore surface and that simply increasing the number
should not lead to higher levels of incorporation in the coat. These strains, however,
would carry an intact cotB gene (residing at its normal chromosomal locus), so in cells
carrying a thyA::cotB-vp28 insertion (i.e., AC01), we would predict that 50% of displayed
CotB proteins would present a wild-type CotB, and 50% would be CotB-VP28. In a
double thyA thyB insertion strain (AC02), we would predict that66% of displayed CotB
proteins would present VP28, and 33% would express wild-type CotB. Although
speculative, the stoichiometric ratio of CotB-VP28 and CotB might help explain the
ELISA detection data of VP28 as shown in Fig. 4B.
Reversion. An insertion generated by a double-crossover recombination event
should be inherently stable, yet there exists the possibility of acquisition of a compen-
satory suppressor or bypass mutation. To address this, we conducted a straightforward
experiment to determine whether upon repeated culture in the absence of any selective
pressure, the thymine dependence could be lost. As shown in Table 2 repeated culture
and reculture of SH14 (thyA::cotB-tcdA26–39 thyA::cotC-tcdA26–39) yielded no loss of
thymine dependency, showing that the insertions were stable and suggesting that the
acquisition of compensatory mutations, if they were to occur, must be an extremely
rare event.
In vivo fate of spores lacking thyA and thyB in the GI tract. It has been demonstrated
that for E. coli to colonize the murine gastrointestinal (GI) tract, synthesis of purines and
pyrimidines is necessary (38). This implies that the low levels of purines and pyrimidines
that might result from digested food or from spurious lysis of resident gut microbiota
might not be sufﬁcient to permit growth of a B. subtilis thyA thyB mutant. In humans,
the intestinal concentration of thymidine is estimated as 0.075 M, and in pigs it is1.0
M (39). We gave mice a single oral dose of 2 109 spores of SH250 (thyA thyB Cmr)
or of SH14 (thyA::cotB-tcdA26–39 thyA::cotC-tcdA26–39) by gavage. Subsequent shedding
of heat-resistant spores in freshly voided feces was determined. For SH250, the strain
carried a silent insertion of the cat gene (chloramphenicol acetyltransferase), so after
serial dilution, counts of heat-resistant CFU were determined on chloramphenicol
plates. SH14 spores were shed in the feces and could be detected only on agar plates
supplemented with thymine, but when spores were plated on agar lacking thymine, no
CFU could be detected (Fig. 6). After 10 days the number of SH14 spores being shed in
the feces was at levels (103 spores/g of feces) at the threshold of detection. These
in vivo data show that the kinetics of shedding of spores lacking both thyA and thyB is
indistinguishable from that of spores of a wild-type strain. We have conﬁrmed that
SH14 spores germinate efﬁciently and as well as wild-type spores (data not shown).
Although it is not possible to deﬁnitively determine whether SH14 spores could
proliferate in the GI tract, it was possible to show that thyA thyB spores that had
transited the GI tract were unable to survive in the absence of thymine. Also, there was
no evidence of reversion or acquisition of markers that might enable germinated spores
to survive.
Utility of spore display. We used three exemplars to demonstrate that spores
carrying insertions at the thyA and thyB loci were suitable for applied purposes, as
TABLE 2 Reversion
Culture rounda
Growth in culture 1 (CFU/ml) Growth in culture 2 (CFU/ml)
DSM  thymine DSM DSM  thymine DSM
1st 2.8  108 0 2.1  108 0
2nd 1.8  108 0 3.4  108 0
3rd 1.85  108 0 1.73  108 0
4th 1.82  108 0 1.6  108 0
5th 1.54  108 0 2.4  108 0
aTwo 25-ml cultures of SH14 (thyA::cotB-tcdA26–39 thyA::cotC-tcdA26–39) were made in DSM with () thymine
(50 g/ml). For the ﬁrst culture round, cells were grown for 24h at 37°C, and samples were analyzed for
CFU counts on DSM agar with or without thymine (50 g/ml). A sample was also used to subculture fresh
medium (25 ml), and the process was repeated four times (2nd to 5th rounds).
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vaccine delivery vehicles, for conjugation of proteins to the spore surface, and ﬁnally for
display of active enzymes. As vaccines we used SH14 spores that express the TcdA26–39
antigen of C. difﬁcile fused to two spore coat protein anchors, CotB and CotC. SH14 is
equivalent to strain PP108 that has previously been shown to confer protection against
C. difﬁcile infection (CDI) in murine and hamster models of infection (4, 27). We
immunized mice with spores of SH14 and PP108 using oral administration, and after a
total of four doses, we measured TcdA26–39-speciﬁc IgG (Fig. 7A) and IgA (Fig. 7B) levels
in the serum and feces, respectively. Compared to results with the control groups (naive
animals and mice dosed with naked PY79 spores) that exhibited no responses, both
PP108 and SH14 spores generated high titers of IgG and IgA, and based on previous
work, we would predict that these levels of antibodies would be protective.
For conjugation of proteins to streptavidin displayed on the spore surface, we
ﬁrst biotinylated a rabbit polyclonal TcdA26–39-speciﬁc antibody and demonstrated
that the antibody had conjugated to SH16 spores using immunoﬂuorescence
FIG 6 Survival in the murine GI tract. Mice (n  5/group) were given a single oral dose of spores (2 
109) of SH14 carrying insertions in the thyA and thyB loci or of SH250, an essentially wild-type strain
tagged with a chloramphenicol resistance marker. The numbers of heat-resistant spores in feces was
determined for 12 days postdosing. SH14 numbers were determined on agar supplemented with
trimethoprim and thymine (). In the absence of thymine, no CFU were detectable (}). SH250 CFU
counts were determined on agar supplemented with chloramphenicol ().
FIG 7 Immunogenicity of SH14 spores expressing the C. difﬁcile TcdA26–39 antigen. Spores (5  1010) of SH14
(thyA::cotB-tcdA26–39 thyB::cotC-tcdA26–39), PP108 (amyE::cotC-tcdA26–39 thrC::cotB-tcdA26–39), and PY79 (spo) were
administered to mice (n  4) by oral gavage on days 1, 14, 35, and 57. Serum IgG and fecal IgA levels speciﬁc to
TcdA26–39 were determined by ELISA, and endpoint titers are shown. **, P  0.005; ***, P  0.0002.
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detection (Fig. 8A), and also conﬁrmed this by using whole-spore ELISA (data not
shown). Using these conjugated spores, we asked whether SH16 spores displaying
TcdA26–39 IgG could remove C. difﬁcile toxins from a crude cell-free lysate. As shown in
Table 3, incubation of conjugated spores with toxin-containing lysates for just 5 min
reduced toxicity by 90%. Interestingly, PY79 spores also had some ability to bind
TcdA26–39 antibodies and were able to provide a modest reduction (10 to 20%) in toxin
activity. Used as an example, this experiment demonstrates that spores might have
potential for therapeutic purposes, for example, in the oral administration of antibodies.
Enzymes are commonly included in animal feeds where they improve digestion and
nutrition. Proteases and amylases are pertinent examples used here to show that it is
possible to display on the spore surface an enzyme that retains activity. Using casein
agar, we showed that SH20 spores expressing the alkaline protease, subtilisin E, carried
enzymatic activity (Fig. 8B). In liquid suspensions we found that 1010 spores of SH20
had 0.13 units of protease activity. Similarly, SH18 spores expressing amylase were
FIG 8 Conjugation of antibodies to spore-displayed streptavidin and enzyme display. (A) Visualization of
conjugation of anti-TcdA26–39 antibodies to SH16 spores (top panel) using immunoﬂuorescence. As a
control, PY79 spores lacking SA failed to conjugate (middle panel). The phase-contrast image conﬁrms
the presence of PY79 spores (bottom panel). (B) Activity of subtilisin E displayed on the spore surface.
Casein agar was used to visualize protease activity. Plates were spotted with 20 l of suspensions of SH20
(thyA::aprE thyB::MCS) or PY79 spores. In each case the inoculum carried 5  108 spores. As a positive
control, 0.02 U of Streptomyces griseus protease (P5147; Sigma) was applied. After 24 h of incubation at
37°C, plates were stained with bromocresol green and incubated for 30 min at RT to reveal zones of
degradation. (C) Starch plates stained with Lugol solution. Suspensions of pure spores of SH18 (109 and
1010 CFU) or PY79 (1010 CFU) were spotted on plates and incubated for 48 h. Plates carried three
antibiotics to prevent bacterial growth. Spores displaying active amylase produced a zone of clearing.
TABLE 3 Subtraction of C. difﬁcile toxinsa
Mixture Cytotoxicity (%)
Medium only 0
Toxins only 100
PY79-treated spores  toxins 80–90
SH16-conjugated spores  toxins 10
aCytotoxicity in HT29 cells was measured using crude toxins from C. difﬁcile or from the same toxins
pretreated with SH16 spores conjugated with a polyclonal antibody to TcdA26–39 or with PY79-treated
spores.
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found to be able to express active amylase on their surfaces (Fig. 8C), and 1010 spores
carried 3 units of amylase activity.
Summary. We have described a straightforward method to contain genetically
modiﬁed bacterial spores. Our approach is conceptually similar to methods described
for Lactobacillus acidophilus (40) and Lactococcus lactis (39) that rely on the indigenous
suicide resulting from a thymineless death. First described in 1954 (22), thymine
dependence differs from other auxotrophies in that the absence of thymine is bacte-
ricidal, and so bacteria carrying defects in the thymidylate synthase genes cannot
accumulate in the environment. Bacillus species carry two thymidylate synthase genes
(thyA and thyB) and require inactivation of both loci to achieve complete dependence
on thymine. We have demonstrated here a two-step cloning procedure requiring
insertional inactivation of ﬁrst the thyA locus and then the thyB locus that renders
recipient cells thymine dependent. Our approach does not require the introduction of
antibiotic resistance markers for selection but, rather, the development of increasing
levels of resistance to trimethoprim that arise from successive disruption of the folate
pathway. Coupled with the temperature-sensitive phenotype of thyA thyB recombinant
strains, this method enables both selection and screening of insertions although
technically there are a number of constraints that must be considered. We show that
the absence of thymine is bactericidal, and we observe no evidence for reversion or
suppression despite repeated passage of these strains. Of course, the purpose of our
cloning system is to construct Bacillus strains able to express proteins for applied
purposes, for example, for the expression of heterologous antigens or enzymes. We
have used examples here showing that chimeric proteins comprised of a heterologous
protein fused to a spore coat protein can be displayed on the spore surface. This has
included the delivery of two enzymes (subtilisin E and alpha-amylase), putative vaccine
protective antigens, as well as streptavidin, which was used here for conjugation to a
polyclonal antibody. It is clear, though, that this system could equally be used for
expression of proteins in, or secretion from, the vegetative cell.
MATERIALS AND METHODS
Strains, medium, and general methods. PY79 is a prototrophic strain of B. subtilis derived from the
type strain 168 (41). PP108 (amyE::cotC-tcdA26–39 thrC::cotB-tcdA26–39) has been described elsewhere (4).
SH250 is a prototrophic derivative of PY79 carrying the cat gene (encoding resistance to chloramphen-
icol) inserted at the amyE locus. General methods for work with B. subtilis, including the two-step
transformation procedure, were performed as described previously (42). DSM is a standard medium for
growth and sporulation of B. subtilis (43). For Western blotting, puriﬁed spores were prepared, and 2 
108 spores were suspended in 40 l of Bolt LDS buffer (Life Technologies) and incubated at 95°C for 10
min. The spore suspension was centrifuged (10 min at 18,000  g), and 20 l of supernatant was run on
a 12% SDS-PAGE gel.
Primers. DNA primers used for PCR ampliﬁcation are shown in Table 4.
pThy vectors. pThyA (4,274 bp) carried a 1,910-bp segment comprising the left (900 bp) and right
(950 bp) arms of the B. subtilis thyA gene surrounding a multiple cloning site (MCS) cloned into pMA-RQ
(2,556 bp; Genscript, USA). Both arms carried additional proximal and distal DNA sequences adjacent to
thyA. Similarly, pThyB1 (4,973 bp) carried a 2,057-bp segment comprising the left (900 bp) and right (1.1
kb) arms of the B. subtilis thyB gene surrounding an MCS cloned into pBluescript SK() (2,958 bp).
TABLE 4 PCR primer list
Primer namea 5=–3=b Purpose
aprE-F TATAAAGCTTGTGAGAGGCAAAAAGGTATG Ampliﬁcation of aprE
aprE-R TATAGAATTCTTACTGAGCTGCCGCCTGTAC
amyE-F TATAAAGCTTGAAACTGCAAACAAATCGAA Ampliﬁcation of amyE
amyE-R TATAGAATTCTTAATGCGGAAGATAACCGTTTAA
cotB-F TATAGGATCCACGGATTAGGCCGTTTG Ampliﬁcation of cotB and fusion to aprE or amyE
cotB-R TATAAAGCTTGGATGATTGATCATCTGAAGATTTTAG
thyA-F GTCTAAATGGAGAAAAAGTGGATC Veriﬁcation of the thyA gene with or without insertion
thyA-R GTTAAGGCCATTGCGTCTAATTC
thyB-F GATATTAAAACAAATCCGAACTC Veriﬁcation of the thyB gene with or without insertion
thyB-R GTCAGACACATAGAATTG
aF, forward; R, reverse.
bEmbedded restriction endonuclease sites (HindIII, EcoR1, and BamH1) are in boldface.
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Plasmids carried the bla gene, and the nucleotide sequences of the thyA and thyB segments are given
in Table S1 in the supplemental material and shown schematically in Fig. 1. pThyA and pThyB plasmids
were constructed which carried chimeric genes inserted at the MCSs of each vector. Chimeric genes (not
optimized for codon usage) containing an in-frame fusion between the 5= segment of B. subtilis cotB or
cotC to the vp26, vp28, tcdA26–39, or SA gene coding ORF were ﬁrst synthesized with suitable 5= and 3=
ends for subcloning in the MCSs of the pThyA and pThyB vectors. For two genes, aprE and amyE, we
ampliﬁed fragments from chromosomal DNA templates and then fused them to cotB. The aprE gene
(encoding subtilisin E) was PCR ampliﬁed from a B. subtilis strain (SG115) in our collection, and the
ampliﬁed coding segment lacked the N-terminal regions involved in protein secretion (presequence) and
activation (prosequence) (44). The amyE gene (encoding alpha-amylase) was ampliﬁed from a lab strain
of Bacillus amyloliquefaciens and was cloned devoid of the secretory signal sequence. The gene fusions
used for this work are shown in Fig. S1.
Construction of B. subtilis strains carrying thyA and thyB insertions. The procedure developed
here consisted of two steps. In the ﬁrst stage, cells of a wild-type recipient strain (in the work described
here the prototrophic strain PY79 was used) were made competent using a two-step transformation
procedure described by Dubnau and Davidoff-Abelson (45) and in common use in Bacillus labs (45, 46).
pThyA plasmids carrying the chimeric gene were linearized with either ApaLI or ScaI digestion, and cells
were plated on SMM (42) agar supplemented with thymine (50 g/ml) and trimethoprim (3 g/ml). After
72 to 96 h of growth, single colonies were colony puriﬁed and assessed for growth at 37°C and 46°C on
SMM agar with or without thymine (50 g/ml) and trimethoprim (3 g/ml). Cells carrying an insertion
at the thyA locus could grow at 37°C with or without thymine but were unable to grow at 46°C unless
supplemented with thymine. A further veriﬁcation was to amplify, by PCR, the presence of the chimeric
gene from transformants using primers annealing to the thyA sequences. Typically, transformation
frequencies were about 2  103 transformants/g of competent cells, with about 15 to 20% of colonies
carrying the correct insertion (see explanation below). In the second stage, a linearized (ApaL1 or Sca1)
pThyB plasmid carrying a chimeric gene was introduced into cells of the thyA insertion strain by
electroporation. Electroporated cells were plated on SMM containing 0.2% (wt/vol) CAA (SMM-CAA)
containing thymine (50 g/ml) and trimethoprim (6 g/ml) and incubated at 37°C for 48 h. To conﬁrm
the presence of both a thyA and a thyB insertion, colonies were streaked on SMM-CAA agar with or
without thymine (50 g/ml) and grown at 37°C. Cells carrying two insertions were unable to grow at both
37°C and 46°C unless supplemented with thymine. A ﬁnal veriﬁcation was made using PCR primers that
ampliﬁed the two insertions. Using electroporation, integration frequencies were about 1  103
insertions/g of linear DNA, with20% of trimethoprim resistance colonies carrying two insertions (thyA
and thyB).
Electroporation. The procedure used here was modiﬁed from established methods (47) for elec-
troporation in Bacillus primarily with the use of SOC2 medium that contained no yeast extract. SOC2
medium contains tryptone (2%, wt/vol), NaCl (10 mM), KCl (2.5 mM), MgCl2 (5 mM), MgSO4·7H2O (5 mM),
and glucose (20 mM). An overnight culture of the strain carrying a thyA insertion was subcultured in 25
ml of SOC2 medium (supplemented with 0.5 M sorbitol) to give a starting OD600 of 0.2. The culture was
grown at 37°C to an OD600 of 1.4, cooled on ice for 10 min, and then harvested by centrifugation at 4°C
(5,000  g, 5 min.). Cells were washed four times in ice-cold electroporation solution (0.5 M sorbitol, 0.5
M mannitol, 10% [vol/vol] glycerol) and suspended in 1.6 ml of the same ice-cold solution. The cells were
now electrocompetent and ready for immediate use. Cells were kept on ice and used within 30 min
although aliquots could be stored at 80°C. Linearized plasmid DNA (1 l, or 50 ng) was added to 60
l of electrocompetent cells, and the mixture was transferred to a prechilled cuvette (1-mm gap width)
and incubated for 1.5 min on ice. The cuvette was then placed inside the electroporator (Bio-Rad
GenePulser Xcell), and the following parameters were used for electroporation: voltage, 2,100 V,
resistance, 200 W; time, 5 ms; number of pulses, 1. After electroporation 1 ml of recovery medium (SOC2
medium containing 0.5 M sorbitol and 0.38 M mannitol) was added to the cuvette, and the mixture was
transferred to a 2-ml Eppendorf tube and incubated for 3 h at 37°C, after which cells were serially diluted
and plated on appropriate selective medium.
Whole-spore ELISA. An ELISA was used to detect surface-exposed proteins as described previously
(48). Microplate wells were coated with 50 l of a suspension of pure spores (2  108 spores/well) and
left overnight at 4°C. Plates were blocked with 2% (wt/vol) bovine serum albumin (BSA) for 1 h at 37°C.
Rabbit polyclonal antibodies recognizing either the heterologous antigen expressed on the spore surface
or the whole B. subtilis spore were used as primary antibodies with incubation for 2 h at room
temperature (RT). Anti-rabbit IgG-horseradish peroxidase (HRP) conjugate (1:5,000 in phosphate-buffered
saline [PBS] plus 0.05% Tween 20) was used as a secondary antibody with 1 h of incubation at RT. TMB
(3,3=,5,5=-tetramethylbenzidine) was used as the substrate.
Antibodies. Polyclonal antibodies to VP28 and TcdA26–39 were raised in rabbits using four subcu-
taneous injections (1 mg/dose, every 14 days). Recombinant proteins were complexed with Freund’s
adjuvant and serum puriﬁed using protein A chromatography. VP26 polyclonal antibodies were raised in
mice using puriﬁed recombinant VP26 (rVP26) protein (four intraperitoneal doses at 14-day intervals; 10
g/dose, with Freund’s adjuvant).
Animal studies. All animal work was performed under UK Home Ofﬁce project license PPL 70/8276.
For immunogenicity studies mice (C57 black, female, 7 weeks old) were dosed with preparations of pure
spores of PY79 or SH14. Immune responses to TcdA26–39 in serum and fecal samples were determined
as described previously (4). For longevity studies, BALB/c mice (female, 7 to 8 weeks old) were used. Mice
(n  5) were administered a single dose of pure spores (2  109) of SH14 or SH250 by oral gavage. At
times thereafter, freshly voided fecal samples were collected (3 to 4 pellets) and homogenized, and for
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SH14 feces, serial dilutions were plated on DSM and on DSM agar plates with trimethoprim (6 g/ml) and
thymine (50 g/ml). SH250 fecal dilutions were plated on DSM plates containing chloramphenicol (5
g/ml). Individual SH14 colonies were randomly checked for the presence of the thy insertions using PCR.
Conjugation to streptavidin. Polyclonal antibodies (rabbit; 100 g) raised to rTcdA26–39 protein
were biotinylated using a Lightning-Link Rapid biotin conjugation kit, type A (Innova Biosciences).
Puriﬁed spores (1  109) of strain PY79 or spores expressing CotB-SA (SH16) in 200 l of PBS were mixed
with 1 g of biotinylated antibody and incubated overnight at 4°C. Spores were then washed four times
with PBS and suspended in 1 ml of PBS. A total of 3  108 conjugated spores were used to coat
microplate wells, which were then probed with an anti-rabbit IgG-horseradish conjugate (1:5,000 in PBS
plus 0.05% Tween 20) with 1 h of incubation at RT, followed by three washes before TMB (3,3=,5,5=-
tetramethylbenzidine) color development. As a control, PY79 spores were taken through the same
procedure. For immunoﬂuorescence, 5  106 treated spores of SH16 or PY79 were added to microscope
slides and allowed to air dry. After three washes with PBS, slides were blocked with PBS containing 2%
(wt/vol) BSA plus 0.05% (vol/vol) Tween 20 for 45 min at 37°C. Biotinylated anti-TcdA26–39 antibodies
(1:300 dilution; 200 l) were added to slides, incubated for 30 min at RT, and then washed three times
with PBS–0.05% (vol/vol) Tween 20. Rabbit ﬂuorescein isothiocyanate (FITC)-conjugated serum (F0382 at
a 1:200 dilution; Sigma) was added, and slides were incubated for 30 min at RT. Image analysis was done
with an EVOS FL LED microscope.
Toxin subtraction assays. C. difﬁcile strain RT176 (tcdA tcdB) was grown in TY broth (3% [wt/vol]
tryptose, 2% [wt/vol] yeast extract, and 0.1% [wt/vol] sodium thioglycolate) for 24 h at 37°C. The cell-free
supernatant was ﬁlter sterilized and kept at 4°C until assay. The minimum lethal concentration (MLC) of
supernatant required to cause 100% toxicity to HT29 cells was determined using a 2-fold dilution and
addition of the diluted lysate to HT29 cells, followed by assessment of toxicity using a cell-rounding assay
(4). For the assay, 109 pure spores of SH16 conjugated to TcdA26–39 polyclonal antibodies (see above)
were added to 200 l of 2% McCoy’s medium containing the toxin MLCs (typically, a 1/4,000 dilution).
The mixture was incubated for 5 min at RT, and then cytotoxicity was assessed using HT29 cells followed
by incubation for 24 h. As a control, PY79 spores that had been mixed with TcdA26–39 antibodies (see
above) were used in parallel.
Enzyme activity. Protease activity was determined using a universal protease assay using casein as
a substrate, as described by Sigma-Aldrich (https://www.sigmaaldrich.com/life-science/learning-center/
life-science-video/universal-protease.html). Casein agar was 1% (wt/vol) casein, 1% (wt/vol) skim milk,
and 1.2% (wt/vol) agar (technical, no. 2; Oxoid). Amylase activity in liquid was measured as described
previously (49). Production of active amylase was tested by applying suspensions of spores (volume of
20 l) to agar plates carrying only soluble starch (1%, wt/vol), beef extract (0.3%, wt/vol), and three
antibiotics (10 g/ml trimethoprim, 30 g/ml chloramphenicol, and 30 g/ml erythromycin). Antibiotics
were used to prevent any bacterial growth on the plates, ensuring that activity arose from dormant
spores only. Plates were incubated for 48 h at 37°C, after which the plate was ﬂooded with Lugol solution
(Sigma) for 2 min to reveal zones of starch degradation. Units of amylase activity were determined as
described by Bernﬁeld (50).
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